No Picture
Trading Ideas

Small-Cap Biotech Surges Almost 350% on Cancer-Drug Trial Data

(Bloomberg) — Small-cap drug developer Five Prime Therapeutics Inc. is on track to post one of this year’s biggest daily stock moves after reporting promising data from a mid-stage cancer study.The South San Francisco, California-based biotech firm skyrocketed as much as 349% after a combination of its drug and chemotherapy helped some patients keep their stomach cancer at bay for longer than those receiving just chemotherapy. Should this rally hold, it would be the third biggest single-day move on the New York Stock Exchange and Nasdaq Exchange, according to data compiled by Bloomberg.Its stock-surge trails a pair of micro-caps with …read more […]

No Picture
Trading Ideas

Pfizer CEO Joins Pharma Executives Selling Stock in Rally

(Bloomberg) — Pfizer Inc. Chief Executive Officer Albert Bourla pocketed about $5.6 million after selling stock, the latest executive to reap the rewards of insider share transactions amid a vaccine-fueled rally for some pharmaceutical companies.Bourla disposed of more than 130,000 shares on Monday, according to a filing with the U.S. Securities and Exchange Commission. Sally Susman, executive vice president and chief corporate affairs officer at Pfizer, also offloaded about $1.8 million in stock.Pfizer’s shares soared that day after a report on results from its experimental vaccine with partner BioNTech SE. Anthony Fauci, the top U.S. infectious-disease specialist described the findings …read more […]

No Picture
Trading Ideas

What China's new antitrust rules mean for big tech companies like Alibaba

Shares of Alibaba fell on Wednesday — despite setting a new record for Singles’ Day — after Beijing released draft rules defining what constitutes anti-competitive behavior for the first time ever. CFRA’s John Freeman joins Yahoo Finance Live to discuss the implications of the move for China’s big tech companies such as Alibaba and JD.com. …read more […]

No Picture
Trading Ideas

CEO sells stock worth $5.6 million on same day as Pfizer's COVID-19 vaccine update

The company said on Wednesday the sale was part of a pre-announced trading plan, adopted by Bourla on Aug. 19. Bourla sold 132,508 shares at $41.94 per share, according to a Securities and Exchange Commission filing late Tuesday. “The sale of these shares is part of Dr. Bourla’s personal financial planning and a pre-established (10b5-1) plan, which allows, under SEC rules, major shareholders and insiders of exchange-listed corporations to trade a predetermined number of shares at a predetermined time,” Pfizer said. …read more […]